Phase 2 Prostate Cancer Trial, Recruiting NCT07192120 Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT07192120
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have signed the consent form agreeing to participate.
  • You are 18 years old or older (any gender can apply).
  • You are able to carry out daily activities with little to no limitation, as measured by a standard health scale (confirm with trial site).
  • Your doctor estimates you have a life expectancy of at least 3 months.
  • You have been diagnosed with an advanced solid tumour (confirmed by a lab test) that has stopped responding to standard treatments, that you could not tolerate, or for which no standard treatment exists.
  • You have at least one tumour that can be measured on a scan, or at least one affected bone lesion.
  • Your bone marrow, liver, kidneys, and other organs are functioning well enough to participate (confirm with trial site).

Who may not be able to join:

  • You have been diagnosed with two or more separate cancers in the past 5 years.
  • You have received chemotherapy in the last 3 weeks, or radiation, biological, hormonal, or immunotherapy treatment in the last 4 weeks.
  • You have taken part in another trial using an unapproved drug or therapy in the last 4 weeks.
  • You have cancer that has spread to the brain, bone marrow, the lining of the brain or spinal cord, the brainstem, or is pressing on the spinal cord.
  • You have severe bone damage caused by prostate cancer that has spread to the bones.
  • You still have side effects from previous cancer treatment that have not cleared up sufficiently (confirm with trial site).
  • You have a serious lung condition that affects your breathing or lung function.
  • You have received a vaccine within the last 4 weeks before starting the trial.
  • You have an active infection requiring treatment within the last 7 days.
  • You have serious heart or stroke-related conditions.
  • You have a significant build-up of fluid in body cavities (such as the abdomen or chest) that cannot be managed (confirm with trial site).
  • You have had significant bleeding, a known tendency to bleed, or wounds that are not healing within the past month.
  • You are known to be allergic to the trial drug or any of its ingredients.
  • You have a substance use issue or a mental health condition that may affect your ability to take part in the study.
  • You are known to be dependent on alcohol or drugs.
  • You are pregnant, breastfeeding, or planning to become pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86 0571-86963293

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Registry
ClinicalTrials.gov
Start date
16 January 2026
Est. completion
1 October 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

(Dose-Escalation Stage): Dose-Limiting Toxicity (DLT) and Maximum tolerated dose (MTD) for MHB048C; (Dose-Expansion Stage): Objective tumor response (ORR) determined by investigators according to RECIST v1.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov